Literature DB >> 21804609

Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis.

L M Tho1, S Libertini, R Rampling, O Sansom, D A Gillespie.   

Abstract

Chk1 is a key regulator of DNA damage checkpoint responses and genome stability in eukaryotes. To better understand how checkpoint proficiency relates to cancer development, we investigated the effects of genetic ablation of Chk1 in the mouse skin on tumors induced by chemical carcinogens. We found that homozygous deletion of Chk1 immediately before carcinogen exposure strongly suppressed benign tumor (papilloma) formation, and that the few, small lesions that formed in the ablated skin always retained Chk1 expression. Remarkably, Chk1 deletion rapidly triggered spontaneous cell proliferation, γ-H2AX staining and apoptosis within the hair follicle, a principal site of origin for carcinogen-induced tumors. At later times, the ablated skin was progressively repopulated by non-recombined Chk1-expressing cells and ultimately normal sensitivity to tumor induction was restored when carcinogen treatment was delayed. In marked contrast, papillomas formed normally in Chk1 hemizygous skin but showed an increased propensity to progress to carcinoma. Thus, complete loss of Chk1 is incompatible with epithelial tumorigenesis, whereas partial loss of function (haploinsufficiency) fosters benign malignant tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804609     DOI: 10.1038/onc.2011.326

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Is activation of the intra-S checkpoint in human fibroblasts an important factor in protection against UV-induced mutagenesis?

Authors:  Christopher D Sproul; Shangbang Rao; Joseph G Ibrahim; William K Kaufmann; Marila Cordeiro-Stone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

2.  CRL4(CDT2) targets CHK1 for PCNA-independent destruction.

Authors:  Jiwon Huh; Helen Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2012-10-29       Impact factor: 4.272

3.  Insulin-like Growth Factor 1 Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-irradiated Human Keratinocytes.

Authors:  Michael G Kemp; Dan F Spandau; Richard Simman; Jeffrey B Travers
Journal:  J Biol Chem       Date:  2016-12-15       Impact factor: 5.157

4.  Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.

Authors:  David W Schoppy; Ryan L Ragland; Oren Gilad; Nishita Shastri; Ashley A Peters; Matilde Murga; Oscar Fernandez-Capetillo; J Alan Diehl; Eric J Brown
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

5.  Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Authors:  Anchit Khanna; Otto Kauko; Camilla Böckelman; Anni Laine; Ilona Schreck; Johanna I Partanen; Agnieszka Szwajda; Stefanie Bormann; Turker Bilgen; Merja Helenius; Yuba R Pokharel; John Pimanda; Mike R Russel; Caj Haglund; Kristina A Cole; Juha Klefström; Tero Aittokallio; Carsten Weiss; Ari Ristimäki; Tapio Visakorpi; Jukka Westermarck
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

Review 6.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

Review 7.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

Review 8.  Checkpoint Responses to DNA Double-Strand Breaks.

Authors:  David P Waterman; James E Haber; Marcus B Smolka
Journal:  Annu Rev Biochem       Date:  2020-03-16       Impact factor: 23.643

Review 9.  Checkpoint kinase 1 in DNA damage response and cell cycle regulation.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Zheng Dong
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

10.  Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.

Authors:  Henry Okuchukwu Ebili; Victoria O Iyawe; Kikelomo Rachel Adeleke; Babatunde Abayomi Salami; Adekunbiola Aina Banjo; Chris Nolan; Emad Rakha; Ian Ellis; Andrew Green; Ayodeji Olayinka Johnson Agboola
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.